How Emerging Pharma Companies Can Succeed in the European Market

Posted by Ben Hohn on Wed, Nov 06, 2019

Judith Kulich, Cody Powers, Amer Dzankic, Mark Rayward-Smith and Renuka Agarwal co-wrote this blog post with Ben Hohn.

The emerging pharma landscape continues to grow in Europe. ZS research shows that around 900 companies are focused on novel therapeutic development, and more than 50% of these companies are concentrated in the U.K., France, Germany and Switzerland, with oncology representing the greatest number of assets (around 30%) as a therapeutic area.


>
Read More

AI Across the Pond: Implementing Next Best Actions in Europe

Posted by Zainul Jafferji on Wed, Jun 27, 2018

There’s no shortage of news about how artificial intelligence techniques are helping us engage customers better in healthcare. Many pharmaceutical companies have visions of Amazon-like targeting serving up Netflix-esque recommendations on how to engage customers better with the right channels, content and cadence.


>
Read More

Highlights From ZS’s 2017 European Summit: What Industry Leaders Really Think About Patient Centricity in Pharma

Posted by Giorgio Lentini on Tue, Oct 31, 2017

Robert Selman and Ausrine Vaisvilaite co-wrote this blog post with Giorgio Lentini. 

Are we already patient-centric simply by talking about patients? Do patients define themselves by their medical conditions or by their roles in life as parents, family members or colleagues?

These were just some of the many questions discussed amongst participants at ZS’s European Summit, which took place in Basel, Switzerland, on Oct. 12.


>
Read More